Scheme 1. Synthesis of Bicyclic 4-N-Carbamoyldeoxycytidine (1, dChpp
)
system of natural nucleobases.2 Here, we describe a new
fluorescent nucleoside dChpp (1) (Figure 1).
the 5-hydroxymethyldeoxyuridine (4). The reaction of 4 with
chlorotrimethylsilane in dioxane followed by treatment with
sodium azide in DMF gave 5-azidomethyldeoxyuridine (5).5
The usual silylation of 5 with TBSCl gave the 3′,5′-O-
protected compound 6. The reaction of 6 with 2,4,6-
triisopropylbenzenesulfonyl chloride followed by ammonoly-
sis gave 5-azidomethyldeoxycytidine derivative (7).6 This
strategy proved to be much superior to the well-known
alternative method by use of POCl3/1,2,4-triazoles7 that gave
a complex mixture. The Pd/C-catalyzed hydrogenation of 7
gave the 5-aminomethyldeoxycytidine 8 in 91% yield.
Intramolecular cyclization of 8 with 1,1′-carbonyldiimidazole
afforded the bicyclic derivative 9 in 84% yield. The silyl
groups of 9 were removed by treatment with tetrabutylam-
monium fluoride hydrate to give dChpp (1) in 89% yield.
The UV absorption spectra of dC, dCcmy, and dChpp
nucleosides in phosphate buffer are shown in Figure 2A.
Different from dC and dCcmy, the spectrum of dChpp exhibited
an interesting absorption band at 300 nm. Furthermore, dChpp
exhibited an emission spectrum (λmax ) 360 nm) when
excited at 300 nm, as shown in Figure 2B.
The quantum yield of dChpp in 10 mM sodium phosphate
(pH 7.0) was caluculated to be 0.12. The absorption spectra
of 4-N-(N-methylcarbamoyl)deoxycytidine derivatives which
have acyclic N-methylcarbamoyl groups at the cytosine
amino group are similar to those of dCcmy, but these acyclic
derivatives did not exhibit any fluorescent properties (data
not shown).
The synthesis of the phosphoramidite 14 is shown in
Scheme 2. For the convenient synthesis of 14, the DMTr
group was first introduced to the 5′-OH group of compound
5. To avoid the deprotection of the DMTr group during
Recently, we have reported the synthesis and properties
of oligodeoxynucleotides containing 4-N-carbamoyldeoxy-
cytidine derivatives.3 It was revealed that the geometry of
the carbamoyl group of 4-N-carbamoyldeoxycytidine (Ccmy
)
derivatives changes depending on the polarity of the solvent.
The NMR analysis of dCcmy in D2O suggested that the
carbamoyl group formed an intramolecular hydrogen bond
with the cytosine ring nitrogen atom so that formation of a
Watson-Crick base pair with the complementary guanine
base was inhibited. However, the Tm analysis showed that
carbamoylation of the 4-amino group of deoxycytidine
allowed the base pairing with a guanine base following the
conformational change of the carbamoyl group. The stability
of DNA duplexes containing a dCcmy-dG base pair was
somewhat low (∆Tm ) -0.6 °C) compared with that of the
unmodified DNA duplex. On the other hand, the acylation
or alkoxycarbonylation4 of the 4-amino group of deoxycy-
tidine did not affect significantly the base pairing with the
guanine. These results imply that destabilization of DNA
duplexes containing dCcmy is due to the energy loss resulting
from the necessity of conformational change of the 4-N-
carbamoyl group. In this paper, we report the synthesis and
properties of a new bicyclic deoxycytidine derivative that
has a conformationally locked 4-N-carbamoyl group. The
carbamoyl group of dChpp and the 5-position of the cytosine
ring are bridged via a methylene linker so that the modified
group does not inhibit the formation of a Watson-Crick base
pair.
The synthesis of dChpp (1) is outlined in Scheme 1.
Treatment of deoxyuridine (3) with paraformaldehyde gave
(2) (a) Okamoto, A.; Tainaka, K.; Saito, I. J. Am. Chem. Soc. 2003, 125,
4972-4973. (b) Okamoto, A.; Tanaka, K.; Fukuta, T.; Saito, I. J. Am. Chem.
Soc. 2003, 125, 9296-9297. (c) Inoue, H.; Imura, A.; Ohtsuka, E. Nucleic
Acids Res. 1985, 13, 7119-7128. (d) Berry, D. A.; Jung, K.-Y.; Wise, D.
S.; Sercel, A. D.; Pearson, W. H.; Mackie, H.; Randolph, J. B.; Somers, R.
L. Tetrahedron Lett. 2004, 45, 2457-2461.
(5) Seio, K.; Wada, T.; Sekine, M. HelV. Chim. Acta 2000, 83, 162-
180.
(6) (a) Sekine, M. J. Org. Chem. 1989, 54, 2321-2326. (b) Matsuda,
A.; Yasuoka, J.; Sasaki, T.; Ueda, T. J. Med. Chem. 1991, 34, 999-1002.
(c) Awano, H.; Shuto, S.; Miyashita, T.; Ashida, N.; Machida, H.; Kira,
T.; Shigeta, S.; Matsuda, A. Arch. Pharm. Pharm. Med. Chem. 1996, 329,
66-72.
(7) (a) Matsuda, A.; Obi, K.; Miyasaka, T. Chem. Pharm. Bull. 1985,
33, 2575-2578. (b) Hodge, R. P.; Brush, C. K.; Harris, C. M.; Harris, T.
M. J. Org. Chem. 1991, 56, 1553-1564.
(3) Miyata, K.; Kobori, A.; Tamamushi, R.; Ohkubo, A.; Taguchi, H.;
Seio, K.; Sekine, M. submitted to Eur. J. Org. Chem.
(4) Wada, T.; Kobori, A.; Kawahara, S.; Sekine, M. Eur. J. Org. Chem.
2001, 4583-4593.
1546
Org. Lett., Vol. 8, No. 8, 2006